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Overexpression of ABCA1 reduces
amyloid deposition in the PDAPP
mouse model of Alzheimer disease
Suzanne E. Wahrle,1 Hong Jiang,1 Maia Parsadanian,1 Jungsu Kim,1 Aimin Li,2
Amanda Knoten,3 Sanjay Jain,3 Veronica Hirsch-Reinshagen,4
Cheryl L. Wellington,4 Kelly R. Bales,5 Steven M. Paul,5 and David M. Holtzman1,6,7,8
1Department

of Neurology, 2Department of Cell Biology and Physiology, 3John T. Milliken Department of Medicine, Renal Division,
Washington University School of Medicine, St. Louis, Missouri, USA. 4Department of Pathology and Laboratory Medicine,
University of British Columbia, Vancouver, British Columbia, Canada. 5Neuroscience Discovery Research, Eli Lilly and Company,
Lilly Research Laboratories, Indianapolis, Indiana, USA. 6Edward Mallinckrodt Department of Developmental Biology,
7Hope Center for Neurological Disorders, and 8Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.

APOE genotype is a major genetic risk factor for late-onset Alzheimer disease (AD). ABCA1, a member of the
ATP-binding cassette family of active transporters, lipidates apoE in the CNS. Abca1–/– mice have decreased
lipid associated with apoE and increased amyloid deposition in several AD mouse models. We hypothesized
that mice overexpressing ABCA1 in the brain would have increased lipidation of apoE-containing lipoproteins and decreased amyloid deposition. To address these hypotheses, we created PrP-mAbca1 Tg mice that
overexpress mouse Abca1 throughout the brain under the control of the mouse prion promoter. We bred the
PrP-mAbca1 mice to the PDAPP AD mouse model, a transgenic line overexpressing a mutant human amyloid
precursor protein. PDAPP/Abca1 Tg mice developed a phenotype remarkably similar to that seen in PDAPP/
Apoe–/– mice: there was significantly less amyloid β-peptide (Aβ) deposition, a redistribution of Aβ to the hilus
of the dentate gyrus in the hippocampus, and an almost complete absence of thioflavine S–positive amyloid
plaques. Analyses of CSF from PrP-mAbca1 Tg mice and media conditioned by PrP-mAbca1 Tg primary astrocytes demonstrated increased lipidation of apoE-containing particles. These data support the conclusions
that increased ABCA1-mediated lipidation of apoE in the CNS can reduce amyloid burden and that increasing
ABCA1 function may have a therapeutic effect on AD.
Introduction
ABCA1, a member of the ATP-binding cassette family of active
transporters, mediates the rate-limiting step of the reverse cholesterol transport pathway, which eliminates excess cellular cholesterol and protects against atherosclerosis (1–5). Specifically, ABCA1
transfers cellular cholesterol and phospholipids onto lipid-poor
apolipoproteins to form pre-β HDL particles in the plasma. These
pre-β HDL lipoprotein particles undergo subsequent cholesterol
esterification and mature into spherical HDL particles that shuttle
cholesterol to the liver for excretion as bile acids. Loss-of-function
mutations in ABCA1 cause Tangier disease, which is characterized
by very low levels of HDL cholesterol and apoA-I in plasma, accumulation of cholesterol in lymphatic organs, and an increased risk
of cardiovascular disease (6–12). The low levels of apoA-I result
from increased degradation of lipid-poor apoA-I (13, 14). In animal models, upregulation of ABCA1 can increase HDL cholesterol
and protect against atherosclerosis (15–17).
ABCA1 also has an important role in the CNS. The CNS contains
HDL-like lipoprotein particles composed mainly of apoE, cholesterol, and phospholipids. Mice lacking ABCA1 have dramatically
Nonstandard abbreviations used: Aβ, amyloid β-peptide; ACM, astrocyte-conditioned media; AD, Alzheimer disease; APP, amyloid precursor protein; CAA, cerebral
amyloid angiopathy; CSF, cerebrospinal fluid; LDLR, LDL receptor; LRP1, LDLRrelated protein 1.
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lower apoE in the plasma, cerebrospinal fluid (CSF), and brain
(18–20), probably because like lipid-poor apoA-I, lipid-poor apoE
is rapidly degraded. Interestingly, CSF from Abca1–/– mice contains a population of apoE-containing lipoprotein particles that
are abnormally small (18). Additionally, nascent apoE-containing
lipoprotein particles secreted from primary cultures of astrocytes,
the major source of apoE in the CNS, are abnormally small and
lipid poor if they are derived from Abca1–/– mice (18). These data
strongly suggest that ABCA1 is the major molecule that lipidates
apoE in the CNS and that the ABCA1 plays as critical a role in
apoE lipoprotein metabolism in the brain as it does in apoA-I and
HDL metabolism in the periphery.
APOE genotype is the major genetic risk factor for late-onset
Alzheimer disease (AD). It is theorized that apoE binds to amyloid
β-peptide (Aβ) and influences its clearance and conformation. For
example, apoE binding may affect the ratio of Aβ that is in a random coil versus a β-sheet (21). Many mouse models of AD have
been created that overexpress mutant human forms of the amyloid precursor protein (APP) and develop AD-like deposits of Aβ
in brain. The Aβ in many of these plaques is arranged into fibrils
with a high β-pleated sheet content that bind the dyes Congo red
and thioflavine S. These fibrillar amyloid plaques are associated
with abnormal axons and dendrites (neuritic dystrophy) and a surrounding area of decreased synaptic density (22). We and others
have shown that apoE contributes to amyloid burden in vivo, as
APP Tg mice that are crossed to mice lacking Apoe develop significantly less Aβ deposition, and strikingly, the Aβ plaques that do
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Since lipid-poor apoE is associated with
increased amyloid deposition in vivo, we hypothesized that increased lipidation of apoE via ABCA1
would lower amyloid deposition. Three transgenic
ABCA1 mouse models have been generated previously; 2 that express genomic ABCA1 as a BAC
(25, 26) and 1 expressing ABCA1 cDNA under the
control of the apoE/C1 locus (27). However, none
of these models have appreciable overexpression
of ABCA1 in the brain. Moreover, crossing ABCA1
BAC Tg mice to APP/PS1 mice did not result in
altered Aβ deposition, likely because brain ABCA1
levels were not significantly increased relative to
those in non-Tg APP/PS1 mice (26). Therefore,
to create mice with abundant overexpression of
ABCA1 in the brain, we cloned the mouse Abca1
cDNA, inserted it into the MoPrP.HD-N171 transgenic mouse vector, produced multiple lines of
transgenic mice, and bred the PrP-mAbca1 Tg mice
to the PDAPP model of AD. In PDAPP cohorts
that overexpressed ABCA1 by 2-fold or more, we
observed not only decreased Aβ deposition, but
also a dramatic decrease in fibrillar Aβ. Overall,
these data demonstrate that selective overexpression of ABCA1 is sufficient to decrease the deposition and fibrillogenesis of Aβ in the brain, likely
by increasing the lipidation of apoE-containing
lipoproteins in the CNS.
Results
Creation and characterization of PrP-mAbca1 Tg mice.
Thirteen founders tested positive for the PrP-mAbca1
transgene by PCR. One founder died before breedFigure 1
Characterization of 3-month-old PrP-mAbca1 mice. (A) Levels of ABCA1 in the cortex ing, 1 founder was sterile, 3 founders failed to
of 5 different lines of PrP-mAbca1 mice (lines D, E, L, J, and G) were visualized by exhibit germline transmission of the transgene, and
Western blotting. RIPA lysates were made from cortex, and equal amounts of total pro- 1 founder did not show overexpression of ABCA1
tein (10 μg) were electrophoresed. Western blotting of ABCA1 was performed using the in the brain. The 7 remaining founders (designated
HJ1 antibody. Samples from Tg (+) and non-Tg mice (–) were compared. Liver lysates B, D, E, G, I, J, and L) all produced pups that were
from Abca1+/+ and Abca1–/– mice were used as positive and negative controls, respecpositive for the PrP-mAbca1 transgene and demontively. The fold difference in ABCA1 overexpression was estimated by diluting the Tg
strated
ABCA1 overexpression in the brain. The
sample until the level of ABCA1 equaled that of the non-Tg sample. (B) ABCA1 expression in multiple brain regions was assessed by Western blotting in PrP-mAbca1 line E progeny of 5 founders bred well and were used for
mice. (C) ABCA1 expression in major body tissues was examined in mice expressing experiments (lines D, E, L, J, and G).
The 5 lines of PrP-mAbca1 Tg mice that we examno ABCA1 (bottom panel), the PrP-mAbca1 transgene with no endogenous ABCA1 (the
top panel), and endogenous ABCA1 (middle panel). Liver lysates from Abca1+/+ and ined had different levels of ABCA1 overexpression
Abca1–/– mice were used as positive and negative controls, respectively.
in the cortex, ranging from approximately 2-fold in
line D to approximately 14-fold in line G (Figure 1A).
Analysis of tissue from the occipital cortex, frontal
form are almost all nonfibrillar and are not associated with neuritic cortex, hippocampus, cerebellum, striatum, septum, and thalamus
dystrophy (20, 23, 24). Since Abca1–/– mice have dramatically lower showed that PrP-mAbca1 Tg mice overexpressed ABCA1 throughlevels of apoE, it might be expected that crossing them to APP Tg out the brain (Figure 1B).
mice would result in a phenotype similar to that of APP/Apoe–/–
Representative tissues from the major organ systems were colmice. However, 3 laboratories independently found that deletion lected to determine the extent of ABCA1 overexpression throughof Abca1 either has no effect on or even increases Aβ deposition out the body. Using Western blot analyses, we detected high endogin 4 different mouse models of AD (20, 23, 24). These results sug- enous mouse ABCA1 expression in lung, liver, spleen, bladder,
gest that the poorly lipidated apoE-containing lipoprotein particles testis, and brain (Figure 1C, middle panel). In comparison, high
produced by Abca1–/– mice may increase Aβ deposition and fibrillo- expression of the PrP-mAbca1 transgene was found in the brain, as
genesis. Additionally, apoE codeposited with fibrillar Aβ (23), and well as in kidney, testis, and muscle (Figure 1C, upper panel). Since
Abca1–/– mice accumulated insoluble apoE to a greater extent than the PrP-mAbca1 Tg mice used in these experiments express endogAbca1+/+ mice (23, 24), demonstrating that lipid-poor apoE binds to enous ABCA1 in addition to the PrP-mAbca1 transgene, they have
fibrillar Aβ in vivo and likely promotes amyloidogenesis.
normal to increased ABCA1 activity in organs outside the brain.
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Figure 2
Spermatogenesis defects in 3-month-old PrP-mAbca1 line E Tg mice. (A) Testes from PrP-mAbca1 line E mice (n = 5) and non-Tg mice (n = 6)
were dissected and weighed. (B) A representative testis from a Tg mouse and a non-Tg mouse. Scale bar: 5 mm. (C) H&E-stained sections
show normal testicular histology in non-Tg mice (top left panel) and marked degeneration of seminiferous tubules of Tg mice (top right panel),
with several multinucleated giant cells (arrowheads) present in almost every tubule compared with their rare occurrence in non-Tg mice. No
elongated spermatids were present in testes from Tg mice. TUNEL staining shows occasional apoptotic cells in testes from non-Tg mice (bottom
left panel) and frequent apoptotic cells in testes from Tg mice (bottom right panel). Scale bar: 50 μm for the top panels and 100 μm for the bottom
panels. (D) Quantification of TUNEL staining in the testes of Tg (n = 4) and non-Tg littermate control mice (n = 4). (E) Sections of testes from Tg
(n = 3) and non-Tg littermate control mice (n = 4) underwent immunohistochemical staining with an anti-GCNA1 antibody that stains germ cells.
The number of GCNA1-positive cells per tubule was tabulated. Statistical analyses of differences between Tg and non-Tg mice were performed
using 2-tailed Student’s t test. **P < 0.01; ****P < 0.0001.

The 5 PrP-mAbca1 Tg lines we studied produced equal numbers
of male and female pups with no overt differences in growth or
health. However, male mice from all but the lowest overexpressing line (line D) were sterile. Gross examination of the testes from
PrP-mAbca1 line E mice revealed severe atrophy in Tg mice, with an
approximately 50% reduction in testes mass compared with nonTg mice (Figure 2, A and B). To further characterize this phenotype, we performed histological examination of the testes of Tg
and non-Tg mice. Compared with non-Tg mice (Figure 2C, top left
panel), the seminiferous tubules of the testes from the Tg mice
showed atrophy with marked degenerative changes highlighted
by a large increase in multinucleated giant cells and cells with
condensed nuclei (Figure 2C, top right panel). These degenerative changes were present in almost every section of the seminiferous tubules in the Tg testes compared with their rare presence in
the non-Tg testes. TUNEL staining showed approximately 3-fold
more apoptotic cells in testes from Tg mice (Figure 2C, bottom
right panel), as compared with non-Tg mice (Figure 2C, bottom
left panel, and Figure 2D). Further, testes from Tg mice exhibited
maturation arrest due to absence of mature products of spermatogenesis such as elongated spermatids and spermatozoa (Figure 2C,
top right panel). These findings are consistent with the marked
reduction in germ cells detected by immunohistochemistry with
an anti-GCNA1 antibody (Figure 2E). The numbers of Sertoli cells,
The Journal of Clinical Investigation

detected by GATA4 immunohistochemistry, were similar in Tg and
wild-type testes (data not shown). A previous study has shown that
Abca1–/– mice have abnormalities in sperm production (28), and
our data suggest that an excess of ABCA1 is also detrimental to
male fertility. However, previous reports on other ABCA1 Tg mice
have not reported any abnormalities in testicle size or male fertility (25, 27, 29). It is interesting that the spermatogenesis defects
reported here are highly similar to those observed in mice with
aberrant glial cell line–derived neurotrophic factor–Ret receptor
tyrosine kinase (GDNF/Ret) signaling (30, 31). Thus, it is possible
that ABCA1 activity directly or indirectly influences the GDNF/
Ret signaling system in the testes.
Amyloid deposition in the brains of PDAPP/Abca1 Tg mice. Mice from
PrP-mAbca1 lines D, E, and J, which overexpressed mABCA1 by
approximately 2-, 6-, and 12-fold, respectively, were bred to the
PDAPP mouse model of AD. The resulting PDAPP/Abca1 Tg mice
and their PDAPP/Abca1 non-Tg littermates were sacrificed at either
3 or 12 months. Brain sections from 12-month-old PDAPP/Abca1
line E mice were stained for Aβ. The PDAPP mice with wild-type
ABCA1 levels (PDAPP/Abca1 non-Tg mice) had frequent punctate
Aβ deposits in the cortex and hippocampus (Figure 3A, top left
panel), including the molecular layer of the hippocampus, but
almost no Aβ deposits in the hilus of the dentate gyrus of the hippocampus (Figure 3A, middle left panel). In contrast, the PDAPP
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strates that Aβ deposits in the PDAPP/Abca1
Tg mice are almost all diffuse, with very little
true amyloid. In the PDAPP/Abca1 Tg mice, the
preferential deposition of Aβ in the hilus of the
dentate gyrus of the hippocampus, along with
the lack of thioflavine S–positive Aβ deposits, is
virtually identical to the pattern of Aβ deposition in PDAPP/Apoe–/– mice. This suggests that
increasing ABCA1-mediated lipidation of apoE
has an effect on Aβ deposition very similar to
that seen in APP Tg mice lacking apoE.
Consistent with previous work (35), the
thioflavine S–positive plaques in the brains of
PDAPP/Abca1 non-Tg mice were associated with
clusters of reactive microglia (Figure 3B, upper
left and lower left panels). The PDAPP/Abca1
Tg mice, which had very few thioflavine S–positive deposits, had few to no observable clusters
of reactive microglia in their brains (Figure 3B,
upper right and lower right panels). These findings demonstrate that the paucity of fibrillar Aβ
in the brains of PDAPP/Abca1 Tg mice is associated with decreased microglial activation.
Quantitative stereological analyses of Aβ
deposition demonstrated markedly and significantly lower Aβ load in the cortex of 12-monthold PDAPP/Abca1 Tg mice as compared with
PDAPP/Abca1 non-Tg littermate control mice
(Figure 4A). The Aβ load in the entire hippocampus did not vary significantly according to
the presence of the mABCA1 transgene, but the
distribution of Aβ within the hippocampus was
altered by the transgene. PDAPP/Abca1 Tg mice
had more Aβ deposition in the hilus of the dentate gyrus and less in the molecular layer (Figure
Figure 3
4A). Quantification of thioflavine S–positive
Aβ staining and thioflavine S fluorescence in the brains of 12-month-old PDAPP/Abca1
line E mice. (A) Sections of brain from PDAPP/Abca1 non-TG mice, PDAPP/Abca1 line amyloid plaques confirmed the near absence of
E mice, and PDAPP/Apoe–/– mice were stained for Aβ using the 3D6 antibody. True amy- true amyloid plaques in PDAPP/Abca1 Tg mice,
loid was visualized by thioflavine S fluorescence. The arrows shown in the middle panels in contrast to the robust presence of amyloid
indicate the upper and lower limits of the hilus of the dentate gyrus. Scale bar: 125 μm plaques in PDAPP/non-Tg mice (Figure 4B).
for the top and bottom panels and 250 μm for the middle panels. (B) Brain sections from Furthermore, thioflavine S–positive amyloid
PDAPP/Abca1 line E mice were immunostained with an antibody against the microglial plaques were quantified in PDAPP/Abca1 lines
marker CD45. Scale bar: 625 μm for all panels.
D, E, and J, which overexpress ABCA1 by 2-, 6-,
and 12-fold in the brain, respectively. Two-fold
overexpression of ABCA1 in the brain decreased
mice with ABCA1 overexpression (PDAPP/Abca1 Tg mice) had rare deposition of thioflavine S–positive amyloid by approximately 50%.
Aβ deposition in the cortex (Figure 3A, top middle panel), occa- Overexpression of ABCA1 by 6-fold or more decreased deposition
sional Aβ deposition in the molecular layer, and frequent Aβ depo- of thioflavine S–positive amyloid to almost 0. These data demonsition in the hilus of the dentate gyrus (Figure 3A, middle panel). strate that overexpression of ABCA1 protects PDAPP mice from
This is interesting because PDAPP mice rarely deposit Aβ in the developing thioflavine S–positive amyloid plaques.
The amount of Aβ in the brains of the PDAPP/Abca1 mice was
hilus of the dentate gyrus unless they also lack Apoe (Figure 3A,
top right and middle right panels) (32–34).
quantified by ELISA at 3 months of age, when Aβ had not yet
Brain sections from the 12-month-old mice were also stained deposited, and after 12 months, when extensive Aβ deposition had
with thioflavine S to detect fibrillar Aβ. As detected via fluorescence occurred. At 3 months of age, both the PDAPP/Abca1 line D and
microscopy, frequent amyloid plaques were seen in the cortex and line E Tg mice, which overexpress ABCA1 by 2- and 6-fold, respechippocampus of the PDAPP/Abca1 non-Tg mice (Figure 3A, bot- tively, had significantly (15%–50%) higher Aβ levels than non-Tg
tom left panel). However, almost no thioflavine S–positive amyloid littermate control mice (Figure 5, A and B, and Table 1). These
plaques were seen in the PDAPP/Abca1 Tg mice (Figure 3A, bottom higher levels do not represent deposited Aβ, as the mice did not
middle panel) or in PDAPP/Apoe–/– mice (Figure 3A, bottom right have histological evidence of Aβ deposition at this age. To deterpanel), even in sections with extensive Aβ deposits. This demon- mine whether the Aβ levels in the young PDAPP/Abca1 Tg mice
674
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Figure 4
Aβ load and thioflavine S–positive plaque load in 12-month-old PDAPP/Abca1 mice. (A and B) Using stereological methods, Aβ staining and thioflavine S fluorescence were quantified in the cortex, hippocampus, and 2 subregions of the hippocampus (molecular layer and hilus of the dentate
gyrus) of PDAPP/Abca1 line E mice. (C and D) Thioflavine S fluorescence was quantified in the cortex and hippocampus of PDAPP/Abca1 line
D, line E, and line J mice. n = 10 for all groups. Statistical analyses of differences between Tg and non-Tg mice were performed using the MannWhitney U test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

were higher due to increased Aβ generation from APP, levels of
APP and the C-terminal fragments (CTFs) created by enzymatic
cleavage of APP were assessed by Western blotting. There were no
differences between PDAPP/Abca1 line E Tg and PDAPP/non-Tg
mice (Figure 5E), suggesting that Aβ production was not likely to
account for the differences in Aβ levels at 3 months. Previously,
our group found that PDAPP/Apoe–/– mice also have higher brain
Aβ levels at 3 months of age, probably because apoE is required for
normal transport and clearance of soluble Aβ (36).
By 12 months of age, large amounts of Aβ had accumulated in the
brains of all mice with the PDAPP transgene (more than 100-fold
compared with 3 months of age). However, mice that also
overexpressed ABCA1 developed significantly less Aβ deposition
than non-Tg littermates. Aβ levels in PDAPP/Abca1 line D Tg mice
were approximately 2.5-fold lower compared with those in PDAPP/
non-Tg littermate control mice (Figure 5C and Table 1), and the
PDAPP/Abca1 line E Tg mice had approximately 3-fold less Aβ in the
brain compared with PDAPP/non-Tg littermate control mice (Figure
5D and Table 1). PDAPP/Abca1 line J Tg mice had a decrease in Aβ
levels at 12 months of age similar to that seen in PDAPP/Abca1 line
E Tg mice (data not shown). As shown in previous studies, PDAPP/
Apoe–/– mice also develop approximately 2- to 3-fold less Aβ deposition than PDAPP/Apoe+/+ mice (32–34). Thus, the PDAPP/Abca1 Tg
mice have a phenotype similar to that seen in PDAPP/Apoe–/– mice.
ApoE levels and solubility in PrP-mAbca1 Tg mice. Previously, we and
others found that Abca1–/– mice have reduced levels of apoE in the
CNS (18–20). This may reflect increased brain catabolism of poorly lipidated apoE produced in the absence of ABCA1, similar to the
rapid turnover of poorly lipidated peripheral apoA-I in ABCA1deficient states. We hypothesized that excess ABCA1 function in
The Journal of Clinical Investigation

the PrP-mAbca1 Tg mice would result in increased apoE lipidation,
which would decrease apoE catabolism. Theoretical support for
this hypothesis was given by the elevated levels of HDL-associated
apolipoproteins in the plasma of previously generated ABCA1 Tg
models (25, 27). Although we expected that the PrP-mAbca1 Tg
mice would have increased levels of apoE in the CNS compared
with non-Tg littermate controls, this was not the case. While 2-fold
overexpression of ABCA1 in PrP-mAbca1 line D Tg mice did not
result in altered apoE levels (Figure 6A), overexpression of ABCA1
by 6-fold or greater resulted in reductions in hippocampal apoE
of approximately 40% compared with non-Tg littermate control
mice (Figure 6A). The size of the decrease did not vary between
lines that overexpressed ABCA1 6-fold to 14-fold, indicating that
the effect is saturable. Also, the extent that ABCA1 overexpression
results in lower levels of apoE varies according to brain region. In
the cortex, apoE was decreased by only approximately 20% in Tg
mice from PrP-mAbca1 lines L, J, and G and was not decreased significantly in lines D or E (Figure 6B). In the CSF, apoE levels were
decreased by approximately 40%–70% in all lines overexpressing
ABCA1 (Figure 6C). PDAPP/Abca1 Tg mice with 6-fold or greater
levels of overexpression also had lower levels of apoE in the brain
at 3 months of age, and the amount of this change was not different from that in non-PDAPP mice (data not shown). To determine whether the decreased apoE levels in the PrP-mAbca1 Tg mice
were due to decreased transcription of apoE, we performed realtime quantitative RT-PCR to determine the relative levels of apoE
mRNA in PrP-mAbca1 line E and line J mice. We found no difference between Tg and non-Tg apoE mRNA levels in either the hippocampus or cortex of either line (Figure 6D and data not shown).
In addition to decreasing apoE levels, overexpression of ABCA1
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Figure 5
Aβ as detected by ELISA in the hippocampus of PDAPP/Abca1 mice.
(A–D) Aβ was serially extracted
from the hippocampus using carbonate and guanidine buffers and
measured by ELISA. The Aβ in the
carbonate and guanidine extracts
was summed, and total Aβ40 and
Aβ42 ares represented. TP, total
protein in the tissue lysate. (A
and B) Aβ in the hippocampus of
3-month-old mice from PDAPP/
Abca1 lines D and E, respectively.
n = 11 in all groups. (C and D) Aβ
in the hippocampus of 12-month-old
mice from PDAPP/Abca1 lines D
and E, respectively. n = 10–14 in all
groups. Statistical analyses of differences between Tg and non-Tg mice
were performed using 2-tailed Student’s t test. *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001. (E)
Levels of APP and APP C-terminal
fragments in hippocampus from
PDAPP/Abca1 line E mice were
visualized by Western blotting. n = 7
for both groups. β-Tubulin was used
as a loading control. Quantification
of the APP and CTF bands using
image analysis software revealed
no significant differences between
PDAPP/Abca1 Tg and PDAPP/
Abca1 non-Tg mice.

affected the biochemical properties of apoE. In all groups of
PrP-mAbca1 Tg mice that overexpressed ABCA1 by 6-fold or greater,
approximately twice as much apoE in the hippocampus and cortex
was insoluble in carbonate buffer and required 5 M guanidine for
extraction compared with non-Tg littermate control groups (data
not shown). The relative insolubility of brain-associated apoE from
PrP-mAbca1 mice in carbonate buffer suggests a difference in apoE
metabolism induced by ABCA1 overexpression.
Plasma levels of cholesterol and apoE were measured in 3-monthold mice of PrP-Abca1 lines D, E, L, J, and G. No differences in plasma apoE levels between Tg and non-Tg mice were observed except
in line J, the second-highest-expressing line, which exhibited elevated plasma apoE levels of 97 ± 6 μg/ml in Tg mice compared with
78 ± 6 μg/ml in non-Tg mice (mean ± SEM; P = 0.04). Plasma cholesterol levels were also not different between Tg and non-Tg mice
except for the 2 highest-expressing lines (J and G), which had higher plasma cholesterol than non-Tg mice. In PrP-Abca1 line J mice,
levels of plasma cholesterol were 647 ± 47 μg/ml in Tg mice and
348 ± 50 μg/ml in non-Tg mice (P = 0.0007). In PrP-Abca1 line G
mice, levels of plasma cholesterol were 586 ± 42 μg/ml in Tg mice
and 418 ± 48 μg/ml in non-Tg mice (P = 0.02). These findings suggest that integration of multiple copies of the PrP-mAbca1 transgene
can affect peripheral cholesterol metabolism through mechanisms
that remain to be identified. In addition to plasma cholesterol,
plasma HDL was assessed in Tg and non-Tg mice by fractionating
plasma from 3-month-old PrP-mAbca1 line E mice using size-exclusion gel chromatography. HDL-associated cholesterol and phospholipids were not significantly different in Tg and non-Tg mice.
676
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Finally, plasma apoA-I levels were assessed by Western blotting in
mAbca1 line E Tg mice versus non-Tg littermates. There was no
significant difference between the groups (data not shown).
apoE-containing lipoprotein particles from PrP-mAbca1 Tg mice. We
previously found that mice lacking ABCA1 had abnormally small
apoE-containing lipoprotein particles in their CSF and that primary astrocyte cultures derived from Abca1–/– mice contained small,
lipid-poor apoE-containing lipoprotein particles (18). We hypothesized that overexpression of ABCA1 in the brain would result in
greater lipidation of apoE-containing lipoprotein particles in the
CSF and that primary astrocytes derived from PrP-mAbca1 Tg mice
would secrete larger, more lipid-rich apoE-containing lipoprotein
particles. Nondenaturing gradient gel electrophoresis of CSF from
PrP-mAbca1 mice, followed by Western blotting for apoE, was performed. apoE-containing lipoprotein particles from the Tg mice
tended to be larger in size than particles from non-Tg mice (Figure
7A). This suggests that apoE particles in the CNS are more lipidated in Tg mice. To further characterize the effects of ABCA1 overexpression on nascent apoE particles, primary cultures of astrocytes
were prepared from PrP-mAbca1 Tg mice and non-Tg littermate
control mice and allowed to secrete apoE-containing lipoprotein
particles into serum-free media over 72 hours. Astrocyte-conditioned media (ACM) from PrP-mAbca1 Tg mice and non-Tg littermate controls was then subjected to nondenaturing gradient gel
electrophoresis followed by Western blotting for apoE. The apoEcontaining lipoprotein particles from the Tg mice had a greater
proportion of lipoprotein particles larger than 11 nm than that
seen in media derived from non-Tg mice (Figure 7B).
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Table 1
Aβ levels in brain extracts as measured by ELISA
Carbonate
Aβ40

Guanidine
Aβ42

Aβ40

Total
Aβ42

Aβ40

Aβ42

3 mo old
Hippocampus
Line D
–, n = 11
+, n = 11
Line E
–, n = 11
+, n = 11

0.36 ± 0.09A
0.49 ± 0.13

0.34 ± 0.04B
0.47 ± 0.15

1.39 ± 0.30
1.62 ± 0.35

2.25 ± 0.54A
2.97 ± 0.91

1.75 ± 0.35A
2.12 ± 0.44

2.59 ± 0.55A
3.44 ± 0.98

0.32 ± 0.07B
0.41 ± 0.05

0.44 ± 0.10A
0.57 ± 0.12

0.80 ± 0.23B
1.32 ± 0.46

1.68 ± 0.36C
3.17 ± 0.52

1.12 ± 0.26B
1.73 ± 0.48

2.11 ± 0.37D
3.73 ± 0.56

0.19 ± 0.05
0.23 ± 0.09

0.34 ± 0.07
0.35 ± 0.08

0.45 ± 0.07
0.05 ± 0.07

0.89 ± 0.12
0.86 ± 0.13

0.64 ± 0.11
0.73 ± 0.12

1.23 ± 0.13
1.21 ± 0.11

0.35 ± 0.05
0.40 ± 0.08

0.34 ± 0.04
0.38 ± 0.05

0.26 ± 0.04C
0.45 ± 0.13

0.97 ± 0.16D
1.66 ± 0.32

0.60 ± 0.07C
0.85 ± 0.19

1.31 ± 0.15D
2.04 ± 0.32

0.86 ± 0.25C
0.49 ± 0.13

2.03 ± 0.47D
0.93 ± 0.36

21.1 ± 5.2D
9.14 ± 4.72

260 ± 73D
103 ± 73

22.0 ± 5.4D
9.63 ± 4.81

262 ± 73D
104 ± 73

0.59 ± 0.12B
0.46 ± 0.08

1.52 ± 0.44D
0.55 ± 0.41

12.0 ± 2.6D
2.34 ± 0.31

132 ± 43
42.3 ± 65.8

12.6 ± 2.7D
2.80 ± 0.33

134 ± 44C
42.8 ± 66.2

0.47 ± 0.15B
0.31 ± 0.10

1.42 ± 0.49C
0.70 ± 0.26

5.95 ± 2.16C
3.29 ± 0.84

81.0 ± 34.3C
33.8 ± 11.1

6.42 ± 2.27C
3.60 ± 0.86

81.0 ± 34.3C
33.8 ± 11.1

0.34 ± 0.07
0.29 ± 0.05

0.83 ± 0.24D
0.40 ± 0.15

3.51 ± 1.15D
1.38 ± 0.18

46.0 ± 22.4B
15.6 ± 21.9

3.84 ± 1.18D
1.66 ± 0.19

46.9 ± 22.5B
16.0 ± 22.0

Cortex
Line D
–, n = 11
+, n = 11
Line E
–, n = 11
+, n = 11
12 mo old
Hippocampus
Line D
–, n = 12
+, n = 12
Line E
–, n = 14
+, n = 10
Cortex
Line D
–, n = 12
+, n = 12
Line E
–, n = 14
+, n = 10

Units are ng of Aβ per mg of total protein. Statistical analyses of differences between Tg and non-Tg mice were performed using 2-tailed Student’s t test.
No footnote, not significant; AP < 0.05; BP < 0.01; CP < 0.001; DP < 0.0001.

To determine whether the astrocyte-derived apoE-containing lipoprotein particles from PrP-mAbca1 mice contained more
lipid, ACM was subjected to size-exclusion gel chromatography
to separate the different classes of lipoproteins. Compared with
astrocytes derived from non-Tg mice, astrocytes derived from Tg
mice secreted less apoE and associated cholesterol in HDL-like
lipoproteins (Figure 7, C and D). However, within the lipoprotein
fractions, there was a significantly greater ratio of cholesterol to
apoE (Figure 7E). This demonstrates that ABCA1 overexpression
resulted in increased lipidation of nascent apoE particles.
Effects of brain overexpression of ABCA1 on other proteins. We used
Western blotting of ABCA1 Tg line E brain lysates to assess whether
overexpression of mAbca1 influenced the levels of other proteins
that are potentially involved in apoE and Aβ metabolism. No differences were found in the levels of low-density lipoprotein receptor
(LDLR), LDLR-related protein 1 (LRP1), and apoA-I when comparing ABCA1 line E Tg mice to non-Tg littermates (Figure 8, A and B).
The level of ABCG1 in brain lysates was also compared by Western
blot in samples from multiple mAbca1 transgenic lines, and there
was no consistent difference found between mAbca1 Tg and non-Tg
mice (data not shown). However, levels of apoJ (also called clusterin)
The Journal of Clinical Investigation

were significantly lower in PrP-mAbca1 line E Tg brain lysates versus
non-Tg control brain lysates (Figure 8, A and B). Because this difference in apoJ levels was not observed in ABCA1 line D mice (data
not shown), a 2-fold overexpression of ABCA1 in the brain is insufficient to significantly alter either apoJ or apoE levels (Figure 6A).
However, lines with greater than 2-fold ABCA1 overexpression
exhibited changes in both apoE and apoJ levels. Notably, because
2-fold overexpression of ABCA1 was sufficient to reduce Aβ levels
in PDAPP/Abca1 line D mice (Figure 5, A and C) without significant
alterations in either apoE or apoJ levels, the beneficial effects of
excess ABCA1 function in Aβ reduction appear to be largely independent of the absolute levels of apoE and apoJ.
Discussion
Our laboratory and others previously showed that ABCA1-deficient mice have decreased levels and poor lipidation of apoE in the
CNS (18–20). Further, when APP Tg mice were bred with Abca1–/–
mice, the APP Tg, Abca1–/– mice developed increased Aβ accumulation and amyloid deposition (20, 23). This result is consistent
with the hypothesis that poorly lipidated apoE is highly amyloidogenic. In the current study, we hypothesized that overexpression of
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Figure 6
Levels of apoE in the hippocampus, cortex, and CSF of 3-month-old PrP-mAbca1 Tg mice. (A and B) apoE was serially extracted from brain
tissue using carbonate and guanidine buffers and measured by ELISA. The apoE in the carbonate and guanidine extracts was summed, and
total apoE is represented in A and B. (C) CSF was diluted, and apoE levels were measured by ELISA. (D) RNA was extracted from the hippocampus and cortex of PrP-mAbca1 line E mice. Real-time quantitative RT-PCR was performed for mouse apoE mRNA and total rRNA. Mouse
apoE mRNA was normalized to total rRNA. (A–D) For all groups, the n = 7–9. Tg and non-Tg samples from the same line were processed
at the same time. Statistical analyses of differences between Tg and non-Tg mice were performed using 2-tailed Student’s t test. *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001.

ABCA1 in the brain would increase apoE lipidation, thereby leading to decreased amyloid deposition. To address this hypothesis,
we created several lines of PrP-mAbca1 Tg mice that overexpress
ABCA1 2- to 14-fold in the brain and bred them to the PDAPP
mouse model of AD. We found that PDAPP/Abca1 Tg mice had (a)
decreased deposition of Aβ; (b) a near absence of thioflavine S–positive amyloid plaques; and (c) a redistribution of Aβ deposits in the
hippocampus from the molecular layer to the hilus of the dentate
gyrus. While alterations of genes and proteins such as secretases,
Aβ-degrading enzymes, and chaperones have been shown to modify Aβ deposition, this triad of findings described above has only
been described in APP Tg mice that lack apoE (32–34, 37). This
phenotype strongly argues that overexpression of ABCA1 in the
brain decreases the amyloidogenic properties of apoE and, further,
that increased apoE lipidation results in a phenotype very similar
to apoE deficiency with respect to Aβ metabolism. These findings
suggest that specifically increasing ABCA1 function or expression
should be explored as a target for AD therapeutics.
The apoE isoform is a major genetic risk factor for AD and
cerebral amyloid angiopathy (CAA) (38–40). The apoE4 isoform
increases risk and apoE2 decreases risk for AD (41). APOE was discovered to be a genetic risk factor for AD after apoE was found to
be a major binding protein for Aβ in human CSF (38, 42). The role
of apoE in the aggregation, deposition, and conformation of Aβ in
the brain in vivo was first shown when APP Tg mice were crossed to
Apoe–/– mice. The phenotype in these mice was striking and similar
to the phenotype observed in the Abca1 Tg mice described here.
In APP Tg mice, the onset of Aβ deposition was unaffected by the
presence or absence of apoE; however, in the absence of apoE, there
678
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was less Aβ accumulation both histologically and biochemically.
Further, throughout the lifespan of APP Tg, Apoe–/– mice, very few
to no fibrillar Aβ deposits including neuritic plaques, CAA, or
CAA-associated hemorrhage ever developed (32, 33, 43, 44). Also,
in PDAPP/Apoe–/– mice, there was a redistribution of Aβ deposits
in the hippocampus to the hilus of the dentate gyrus, where these
deposits are not normally found (34, 37, 45). This cluster of phenotypes has not been seen in mice with other modifications to
APP/Aβ, including elimination of β-secretase or increasing an Aβ
protease such as neprilysin (46, 47). The closest phenotype to that
of APP/Apoe–/– mice is seen in APP Tg mice that lack apoJ, also called
clusterin. However, PDAPP/clusterin–/– mice do not redistribute Aβ
to the hilus or exhibit nearly as dramatic a decrease in fibrillar Aβ
plaques (48) as either Apoe–/– or Abca1 Tg mice. The fact that PDAPP
Tg mice crossed with PrP-mAbca1 Tg mice have a phenotype virtually identical to that seen in PDAPP/Apoe–/– mice strongly argues
that the effect of ABCA1 on Aβ related pathology is via altering the
properties of apoE. Intriguingly, the functional effect of increasing
apoE lipidation is strikingly similar to that of deleting apoE, with
respect to Aβ fibrillization, deposition, or clearance.
There are several additional findings that support the idea that
overexpression of ABCA1 influences Aβ metabolism via apoE. We
previously found that when PDAPP/Apoe–/– mice are 3 months
of age, prior to Aβ deposition, they have an approximately 2-fold
increase in the level of Aβ in soluble brain homogenates and
brain interstitial fluid (36). This is similar to what we observed
in 3-month-old PDAPP/Abca1 Tg mice. Our previous studies in
PDAPP/Apoe–/– mice showed that the increase in interstitial fluid
Aβ observed early in life was due to apoE’s ability to influence Aβ
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Figure 7
Analysis of apoE-containing lipoprotein particles derived from PrP-mAbca1 line E mice. (A) CSF (2 μl) from 3-month-old PrP-mAbca1 line E
mice was run on a nondenaturing gradient gel, and Western blot analysis for mouse apoE was performed. (B) Media conditioned by primary
astrocytes derived from PrP-mAbca1 line E mice was run on a nondenaturing gradient gel, and Western blot analysis for mouse apoE was performed. Samples containing equal amounts of apoE were loaded. (C and D) Primary astrocytes derived from PrP-mAbca1 line E mice secreted
apoE-containing lipoprotein particles into the media over 72 hours. Lipoprotein particles in the ACM were separated by size using gel filtration
chromatography. The levels of apoE and cholesterol were then measured in the fractions and normalized to total protein in the cell pellet. n = 3
for non-Tg and n = 5 for Tg. (E) The amount of cholesterol and apoE in lipoprotein fractions 20–50 was totaled, and lipoprotein cholesterol was
divided by lipoprotein apoE. Two-tailed Student’s t test was performed to evaluate the statistical significance of differences between particles
from Tg and non-Tg mice. ****P < 0.0001.

transport or clearance (36). Thus, the fact that Apoe–/– mice did not
have accelerated Aβ deposition, in spite of higher soluble Aβ early
in life, is likely due to the removal of apoE and its function as an Aβ
binding molecule or pathological chaperone. The overexpression
of ABCA1 that resulted in apoE-containing particles with a larger
size than normal may have resulted in an alteration in the ability of
apoE to influence the time of onset of Aβ aggregation via an effect
on Aβ binding that subsequently influenced Aβ clearance or fibrillogenesis. For example, recent experiments suggest that when Aβ is
injected in the brain alone, it is rapidly cleared from the brain, but
injection of Aβ together with astrocyte-derived apoE results in greater Aβ retention in the brain (49). It is possible that highly lipidated
apoE may increase Aβ transport from brain to blood or alter local
Aβ clearance in such a way as to decrease the probability of Aβ aggregation. These ideas can be directly tested in future experiments.
While we did observe lower levels of apoE in some Abca1 Tg lines,
this was not seen in the PrP-mAbca1 line D or in the cortex of the
PrP-mAbca1 line E mice. The observation that there were lower levels
of apoE in the Abca1 Tg lines with high expression suggests that
increased lipidation of apoE may promote its uptake by members
of the LDLR family. However, since the effect of ABCA1 overexpression on Aβ accumulation and deposition was still marked even in
The Journal of Clinical Investigation

PrP-mAbca1 line D, which did not have lower apoE levels in the brain,
it does not appear that lowered apoE levels are responsible for the
effects on Aβ that we observed. It is also unlikely that the effects of
ABCA1 overexpression or Apoe in APP Tg mice are due to altered Aβ
synthesis, as we found no change in total APP or APP C-terminal
fragments in PDAPP/Abca1 Tg mice. There are also no changes in
APP levels or APP C-terminal fragments observed in Apoe–/– mice
(36). Thus, changes in Aβ production are not likely to account for
the changes we observed in Aβ levels in PDAPP/Abca1 Tg mice.
Our data suggest that treatments that increase the expression
of ABCA1 would likely decrease Aβ deposition, especially fibrillar
Aβ. Activation of the transcription factor LXR has been shown to
increase transcription of ABCA1 and many other genes involved
in lipid metabolism and other pathways (50–52). LXR agonists
have been shown in both in vitro and in vivo experiments to affect
Aβ levels (20, 53–57). Whether the effects of LXR agonists on
human Aβ levels and ultimately deposition in vivo require ABCA1
remains to be determined.
In addition to the positive effects of overexpression of ABCA1 on
Aβ, we did observe that male mice overexpressing ABCA1 at levels
6-fold or greater than those in normal brain were infertile. This
is probably due to overexpression of ABCA1 in the testes, which
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cognitive performance over the lifespan of APP Tg mice that are
Abca1–/– or overexpress ABCA1. The results of these studies could
help further determine whether enhancing ABCA1 function is an
attractive target for AD therapeutics.
Methods

Figure 8
Comparison of lipoprotein receptors and lipoproteins in PrP-mAbca1
line E Tg versus non-Tg mice. (A) Samples of cortex from 3-month-old
mice were lysed in RIPA buffer. Equal amounts of total protein from
each mouse were loaded into each well of the gel and then assessed
by Western blotting for LDLR, LRP, apoJ, apoA-I, and tubulin. Three
representative lanes are shown for Tg and non-Tg mice. (B) Quantitative analysis of Western blots was performed using Kodak Image Station software, with n = 3–6 per group. ****P < 0.0001.

occurs throughout the entire lifetime of the PrP-mAbca1 Tg mice.
It is not clear whether an increase in ABCA1 in adulthood may
compromise male fertility or whether it may be possible to selectively target expression of ABCA1 in the brain versus testes versus
other organs using small molecules. These issues remain to be considered as ABCA1-directed therapies are developed.
The findings that selective ABCA1 deficiency promotes amyloidogenesis whereas selective ABCA1 overexpression lowers
amyloid load demonstrates that ABCA1 is a key regulator of Aβ
aggregation and deposition. The ABCA1/apoE/Aβ axis is therefore
an important area for further investigation. It would be helpful
to understand whether overexpression of ABCA1 directly results
in altered Aβ transport or clearance in vivo as has been shown in
Apoe–/– mice. It would also be important to know how increased
lipidation of brain-derived apoE influences the ability of apoEcontaining lipoproteins to interact with Aβ. Previous in vitro work
has shown that lipidated apoE forms an SDS-stable complex with
Aβ to a greater extent than nonlipidated apoE (58, 59). In addition, lipidated apoE binds with a much higher affinity than poorly
lipidated apoE to soluble Aβ (60). In future experiments, it may be
important to utilize apoE derived from HDL-like particles from
glial cells, the main producer of apoE in the CNS, as the apoEcontaining HDL secreted by these cells differs from plasma HDL
(61, 62). Since decreases or increases in ABCA1 expression alter
the absolute level of apoE without affecting Apoe transcription,
understanding how ABCA1 alters apoE metabolism in the brain
will be important. Finally, while behavioral studies with APP Tg
mice can be difficult to interpret, it may be useful to compare the
680

The Journal of Clinical Investigation

Creation of PrP-mAbca1 Tg mice. Murine Abca1 was cloned from RNA isolated
from mouse liver using the RNeasy kit (QIAGEN). Random primer RT-PCR
was performed using the First Strand cDNA Synthesis Kit (Roche Applied
Sciences) to amplify 4 sections of ABCA1 cDNA that were inserted into the
pcDNA3.1 vector (Invitrogen) and ligated together to make the full-length
mouse Abca1 cDNA. The correct sequence and orientation of the gene was
verified by complete sequencing. Abca1 cDNA was excised from pcDNA3.1
using XhoI and inserted into the cloning site of the MoPrP.HD-N171 TG
mouse vector (63), a kind gift from David Borchelt, University of Florida,
Gainesville, Florida, USA. The vector-insert boundary was sequenced to
verify the proper orientation of the gene, and the Bluescript sequence was
removed by Not I digestion to shorten and linearize the vector. The Mouse
Genetics Core Laboratory at Washington University then produced the Tg
mice using the PrP-mAbca1 transgene.
Animals and tissue collection. All animal experiments were approved by the
animal studies committee at Washington University. All animals used for
in vivo experiments were either 3 or 12 months old. The founders were
on a 50% C57BL/6/50% CBA genetic background and were bred to pure
C57BL/6 mice. The mice used for experiments were from the F2 or F3 generations and were therefore approximately 12.5%–6.25% CBA, respectively,
with the majority of the background being C57BL/6. To control for genetic
background effects, non-Tg littermate mice were always used as controls
in experiments with the PrP-mAbca1 Tg mice from the appropriate line.
Abca1–/– mice were obtained from the Jackson Laboratory.
CSF was obtained as previously described (64). For tissue collection,
animals were anesthetized with pentobarbital and perfused with PBSheparin (3 U/ml). Regional brain dissection and dissection of body tissues was performed. Tissue samples were frozen on dry ice and stored at
–80°C until further analysis.
Testes studies. Testes were harvested and processed as described previously (30, 31). Briefly, the tissue was fixed either in 4% paraformaldehyde
for TUNEL staining and immunohistochemistry or in Bouin fixative followed by paraffin embedding and serial sectioning (6 μM) for histological
analysis. For quantification, 50 seminiferous tubules from random crosssections of each testis were counted. An anti-GCNA1 antibody (1:200, rat
polyclonal; a gift from George Enders, University of Kansas Medical Center, Kansas City, Kansas, USA) was used to identify germ cells, and an antiGATA4 (1:200, goat polyclonal; Santa Cruz Biotechnology Inc.) antibody
was used to identify Sertoli cells.
HJ1. At the time of these experiments, we found no satisfactory commercially available antibody that detected murine ABCA1 on Western blots
and therefore created our own antibody. Using cDNA made from mouse
liver RNA, we cloned the N-terminal extracellular loop of ABCA1 from bp
465–2,184 into the pRSET B vector (Invitrogen) using NcoI and HindII.
The recombinant protein was expressed in E. coli and purified from inclusion bodies. The protein was then used as an immunogen for production
of a monoclonal antibody according to protocols established by the Washington University School of Medicine Hybridoma Center (65).
Western blotting. Tissue was sonicated in 10 μl/mg of RIPA buffer with
protease inhibitors. Total protein in the tissue homogenates was determined by micro-BCA assay (Pierce). Equal amounts of total protein from
each animal were loaded into the wells of pre-made gels from Invitrogen.
Total protein (10 μg) was loaded for higher-abundance proteins (e.g.,
apoE), and 50–80 μg of total protein was loaded for lower-abundance
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proteins (e.g., LRP). After electrophoresis, protein was transferred to nitrocellulose membranes and blocked with 4% milk. The blots were probed with
the following antibodies: anti-ABCA1 (HJ1, described above), anti–apoA-I
(Biodesign K23001R), anti-apoE (Calbiochem 178479), anti-apoJ (Covance
SIG-39080), anti-APP (Zymed 51-2700), anti-LDLR (Novus NB110-57162),
anti-LRP (a generous gift from Guojun Bu, Washington University), antiABCG1 (Novus NB400-132), and anti-tubulin (Sigma-Aldrich T5168). The
blots were then washed and incubated with the appropriate HRP-linked secondary antibody. Bands were visualized with the SuperSignal enhanced chemoluminescence agent (Pierce) and imaged with a Kodak Image Station.
ACM. Astrocytes were cultured, and ACM was fractionated as described
previously (18). Briefly, cerebral lobes were dissected from 1- to 3-day-old
mouse pups, and the meninges were removed. Tissue was triturated and
passed through a 100-μm cell strainer. Cells were grown in 1:1 DMEM/F12
medium containing 10% FBS, 10% horse serum (HS), 10 ng/ml EGF,
1× penicillin/streptomycin, 1× Fungizone, and 1 mM sodium pyruvate.
Serum-free medium contained 1× N2 supplement (Invitrogen) in place of
FBS and HS. Confluent astrocytes were grown in serum-free medium for 3
days, and the conditioned medium was collected.
For fractionation of ACM, 40 ml of media was concentrated into 1 ml with a
10-kDa molecular weight cut-off concentrator (Millipore). The concentrated
ACM was passed through tandem Superose-6 HR 10/30 columns (Amersham
Biosciences). Cholesterol was measured as previously described (18) using the
Amplex Red kit from Molecular Probes (Invitrogen). Phospholipid was measured using the Wako Phospholipids C kit. apoE protein was measured using
a sensitive sandwich ELISA that has previously been described (18).
Nondenaturing gradient gel electrophoresis. Samples of ACM or CSF were
mixed 1:1 with native sample buffer and electrophoresed on 4%–20% TrisGlycine gels (Invitrogen). Proteins with known hydrated diameters were
used as size standards (Amersham). Proteins were transferred to a nitrocellulose membrane, probed with a goat anti-mouse apoE antibody at 1:100
(M-20 from Santa Cruz Biotechnology Inc.), washed, and probed with
horse anti-goat IgG linked to HRP at 1:1,000 (Vector Laboratories). Bands
were visualized with enhanced chemoluminescence (Pierce) and imaged
with a Kodak Image Station.
Measurement of apoE protein in brain and CSF. Brain tissue was subjected
to a serial extraction method that has previously been used to extract different pools of Aβ (36). Tissue was homogenized in 10 μl/mg carbonate
buffer (100 mM sodium, 50 mM NaCl, protease inhibitors, pH 11.5) and
1. Glomset, J.A. 1968. The plasma lecithins:cholesterol acyltransferase reaction. J. Lipid Res. 9:155–167.
2. Van Eck, M., Pennings, M., Hoekstra, M., Out, R.,
and Van Berkel, T.J. 2005. Scavenger receptor BI
and ATP-binding cassette transporter A1 in reverse
cholesterol transport and atherosclerosis. Curr.
Opin. Lipidol. 16:307–315.
3. Lee, J.Y., and Parks, J.S. 2005. ATP-binding cassette
transporter AI and its role in HDL formation. Curr.
Opin. Lipidol. 16:19–25.
4. Brewer, H.B., Jr., Remaley, A.T., Neufeld, E.B., Basso,
F., and Joyce, C. 2004. Regulation of plasma highdensity lipoprotein levels by the ABCA1 transporter
and the emerging role of high-density lipoprotein
in the treatment of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 24:1755–1760.
5. Wang, X., et al. 2007. Macrophage ABCA1 and
ABCG1, but not SR-BI, promote macrophage
reverse cholesterol transport in vivo. J Clin. Invest.
117:2216–2224.
6. Brooks-Wilson, A., et al. 1999. Mutations in ABC1
in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:336–345.
7. Bodzioch, M., et al. 1999. The gene encoding ATPbinding cassette transporter 1 is mutated in Tangier
disease. Nat. Genet. 22:347–351.

centrifuged at 20,000 g for 25 minutes. The carbonate extract was collected, and the pellet was rehomogenized in 500 μl of guanidine buffer
(5 M guanidine, 50 mM Tris, protease inhibitors, pH 8.0). The guanidine
homogenate was rotated for 3 hours at room temperature, then centrifuged at 20,000 g for 25 minutes and the guanidine extract collected. apoE
in carbonate and guanidine brain extracts, as well as CSF, was measured
using a previously described ELISA (18).
Real-time RT-PCR of mouse apoE. Real-time RT-PCR for mouse apoE was
performed exactly as described before (18). Briefly, RNA was extracted from
brain tissue using the RNeasy kit (QIAGEN). RT-PCR for mouse apoE was
performed with the Brilliant SYBR Green QRT-PCR Master Mix 1-Step kit
(Stratagene) and RT-PCR for 18S ribosomal RNA was performed using
reagents from Applied Biosystems. The ABI Prism 7000 sequence detection
system was used for running and analyzing the real-time RT-PCR. Mouse
apoE mRNA was normalized to 18S ribosomal RNA.
Statistics. All analyses were performed using PRISM version 5.00 (GraphPad). Error bars represent SEM. For all tests of significance between 2
groups, either a 2-tailed Student’s t test or a Mann-Whitney U test was
performed. A P value of less than 0.05 was considered significant.
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